oxonic acid has been researched along with Peritoneal Carcinomatosis in 215 studies
Oxonic Acid: Antagonist of urate oxidase.
Excerpt | Relevance | Reference |
---|---|---|
"The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 7.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
" Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer." | 7.77 | A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011) |
"We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1." | 7.74 | Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. ( Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2007) |
"Paclitaxel was used as the first-line drug for treatment of a case with peritoneal recurrence of gastric cancer, accompanied by cancerous ascites." | 7.73 | [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2006) |
"Paclitaxel (PTX) was administered via an IP access port implanted in the subcutaneous space." | 5.42 | Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. ( Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H, 2015) |
"Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes." | 5.40 | Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. ( Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2014) |
"We report two cases of advanced gastric cancer." | 5.38 | [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel]. ( Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S, 2012) |
" Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites." | 5.36 | Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
"After the 5th course, the stenosis of colon and ascites had disappeared in a barium enema and CT scan, respectively." | 5.32 | [A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1]. ( Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H, 2003) |
"The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 3.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
"A total of 123 patients with unresectable or recurrent gastric adenocarcinoma with peritoneal metastasis receiving intravenous and intraperitoneal paclitaxel combined with S-1 were retrospectively studied." | 3.78 | Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis. ( Emoto, S; Hirano, K; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Yamaguchi, H; Yamamoto, N, 2012) |
" Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer." | 3.77 | A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011) |
"We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1." | 3.74 | Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. ( Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2007) |
"Paclitaxel was used as the first-line drug for treatment of a case with peritoneal recurrence of gastric cancer, accompanied by cancerous ascites." | 3.73 | [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2006) |
" The mean values of 5-fluorouracil (5-FU) concentrations in ascites of the S-1 group at 1-4 h were 414-580 ng/ml (n=5), and those of FT group were 70-87 ng/ml (n=5), with significant differences between the two groups at each observation time." | 3.72 | Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. ( Hirakawa, K; Nakata, B; Yamagata, S, 2004) |
"The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive." | 3.11 | Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. ( Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z, 2022) |
"Six patients with gastric cancer with peritoneal metastasis were enrolled." | 3.01 | Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study). ( Hayata, K; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2021) |
" Recently, superiority of IP administration of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis." | 2.94 | Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis. ( Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H, 2020) |
"Gemcitabine was administered at a dose of 1000 mg/m2 by 30 min infusion on days 1, S-1 40 mg/m2 orally twice daily and LV 25 mg orally twice daily on days 1 to 7 every 2 weeks." | 2.90 | A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. ( Hakuta, R; Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kishikawa, T; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Saito, T; Sasaki, T; Tada, M; Takahara, N; Takeda, T; Tateishi, K; Uchino, R; Yamamoto, N, 2019) |
" Major grade 3/4 adverse events during NAC were neutropenia (29." | 2.90 | Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). ( Boku, N; Hirao, M; Ito, Y; Iwasaki, Y; Kaji, M; Katai, H; Katayama, H; Kimura, Y; Kurita, A; Mizusawa, J; Nakamura, K; Sano, T; Sasako, M; Takagi, M; Terashima, M; Yamada, M; Yoshikawa, T, 2019) |
"Patients diagnosed with CY+ advanced gastric cancer and treated with S-1-based therapy were enrolled." | 2.84 | Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. ( Chin, K; Hiroki, O; Ichimura, T; Matsushima, T; Nakayama, I; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2017) |
"Paclitaxel was administered i." | 2.84 | Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. ( Fujii, T; Honda, G; Isayama, H; Ishigami, H; Kodera, Y; Kon, M; Kurata, M; Mizuma, M; Motoi, F; Satoi, S; Takahara, N; Unno, M; Yamada, S; Yamamoto, T; Yanagimoto, H, 2017) |
" Grade 3 or worse adverse events were less frequent in the elderly group receiving SOX than in the elderly group receiving CS except for the low incidence of sensory neuropathy (5." | 2.82 | Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. ( Amagai, K; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tanabe, S; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2016) |
"Postoperative complications were identified in 18 patients and the overall morbidity rate was 26." | 2.79 | Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy. ( Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Morita, S; Nishikawa, K; Ogata, T; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2014) |
" This phase 2 study evaluated the benefits and tolerability of weekly intravenous and intraperitoneal paclitaxel (PTX) treatment combined with oral S-1 in patients with gastric cancer who had macroscopic peritoneal metastasis." | 2.78 | A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. ( Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2013) |
"Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases." | 2.78 | Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013) |
"S-1 in patients with advanced gastric cancer (AGC)." | 2.78 | Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer. ( Lu, XY; Wang, ML; Wang, X; Yang, JF; Yu, HG; Zhou, LY, 2013) |
"The standard of care for gastric cancer with peritoneal metastasis is chemotherapy." | 2.77 | [The updated treatment strategy for gastric cancer with peritoneal metastasis]. ( Ishigami, H; Kaisaki, S; Kitayama, J, 2012) |
"Paclitaxel was administered intraperitoneally at 80 mg/m(2)." | 2.77 | A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. ( Furukawa, H; Imamoto, H; Imano, M; Inoue, K; Itoh, T; Kato, H; Nishida, S; Nishikawa, M; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Takeyama, Y; Tsubaki, M; Yasuda, A; Yasuda, T, 2012) |
"Eighteen patients with advanced gastric cancer in addition to confirmed peritoneal metastasis using laparoscopy were enrolled in this study." | 2.76 | Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study. ( Higashijima, J; Iwata, T; Kurita, N; Miyatani, T; Morimoto, S; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2011) |
" paclitaxel (PTX) combined with S-1 was carried out in gastric cancer patients with peritoneal metastasis." | 2.75 | Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
"CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy." | 2.75 | Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. ( Ito, S; Kodera, Y; Kojima, T; Mochizuki, Y; Nakanishi, H; Yamamura, Y, 2010) |
"Twelve gastric cancer patients with positive cytology were enrolled in this study." | 2.75 | Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. ( Doki, Y; Fujiwara, Y; Miyata, H; Moon, JH; Mori, M; Nakajima, K; Nishida, T; Takiguchi, S; Yamamoto, K; Yamasaki, M, 2010) |
"Patients with advanced gastric cancer, naive to chemotherapy or not refractory to fluoropyrimidine, were enrolled." | 2.75 | Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer. ( Boku, N; Hironaka, S; Kojima, T; Machida, N; Muro, K; Shitara, K; Taku, K; Ueda, S; Yamazaki, K; Yokota, T, 2010) |
" A pharmacokinetic study of PTX was also performed." | 2.74 | Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2009) |
"The prognosis of advanced gastric cancer patients complicated with positive lavage cytology is poor, similar with that of peritoneal dissemination." | 2.73 | [Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy]. ( Iwagami, S; Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Nunobe, S; Ohashi, M; Takahashi, K; Yamaguchi, T, 2008) |
"An early detection and treatment of gastric cancer with peritoneal dissemination are rather difficult so that a clinical trial has been neglected." | 2.73 | [Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination]. ( Doki, Y; Fujiwara, Y; Miyata, H; Monden, M; Nishida, T; Takiguchi, S; Yamazaki, M, 2007) |
"To determine the safety profile and activity of IP docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer, a multi-centric phase I/II study has started." | 2.73 | [A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer]. ( Fujimura, T; Fukushima, N; Fushida, S; Goda, F; Hirono, Y; Imano, M; Kaji, M; Kurita, A; Kurita, N; Nashimoto, A; Ohta, T; Tanemura, H; Tsujitani, S; Watanabe, Y; Yamaguchi, K, 2007) |
"We treated 12 patients with advanced gastric cancer with 80 mg/m2 of S-1 for 21 days and 60 mg/m2 of cisplatin (CDDP) on day 8 every 5 weeks." | 2.71 | Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2003) |
"S-1 showed promising activity against gastric cancer with peritoneal dissemination and acceptable toxicity." | 2.71 | Pilot study of S-1 in patients with disseminated gastric cancer. ( Hayashi, K; Kitamura, Y; Oguma, H; Sasagawa, T; Takasaki, K, 2003) |
"TS-1 is a promising drug for gastric cancer with peritoneal dissemination." | 2.70 | [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
"Nearly 70% of gastric cancer recurrences occur as peritoneal dissemination." | 2.55 | [A Case of QOL Improvement after Intestinal Stenosis Due to Peritoneal Dissemination of Gastric Cancer in Elderly Patients]. ( Furuke, Y; Ikeda, J; Imura, K; Komatsu, S; Kumano, T; Nakatsugawa, Y; Shimomura, K; Shioaki, Y; Tanaka, Y; Taniguchi, F, 2017) |
"Advanced gastric cancers have a poor course in terms of the development of peritoneal carcinomatosis and prognosis, even if the curative resection has been performed." | 2.55 | The Importance of Extensive Intraoperative Peritoneal Lavage as a Promising Method in Patients with Gastric Cancer Showing Positive Peritoneal Cytology Without Overt Peritoneal Metastasis and Other Therapeutic Approaches. ( Alemdar, A; Bas, K; Ilhan, E; Ureyen, O, 2017) |
"A 64-year-old man with type 3 advanced gastric cancer was referred to our hospital." | 2.52 | [A case of highly advanced gastric cancer with peritoneal dissemination -- a histological CR to S-1 and CDDP combination chemotherapy]. ( Ito, S; Ito, Y; Kurahashi, S; Misawa, K; Niwa, Y; Shimizu, Y; Yatabe, Y, 2015) |
"An 80-year-old man with type 4 gastric cancer in the mid-gastric region underwent total gastrectomy and D2-No." | 2.52 | [Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination]. ( Ito, M; Kitano, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakajima, Y; Nakatani, M; Tanaka, T; Wakatsuki, K, 2015) |
"The patient was a 71-year-old man with gastric cancer of Borrmann type 3 accompanied with N3." | 2.49 | [Curative resection of a case of advanced gastric cancer with peritoneal dissemination responding well to combination chemotherapy of docetaxel,cisplatin and S-1]. ( Atsumi, Y; Hasegawa, S; Imada, T; Masuda, M; Nemoto, H; Oshima, T; Rino, Y; Sato, T; Tamagawa, H; Uchiyama, M; Yoshikawa, T; Yukawa, N, 2013) |
"Hence, he was diagnosed with advanced jejunal cancer with distant metastasis (T4N1M0 stage)." | 2.49 | [A case of jejnal cancer who was controlled peritoneal metastasis, successfully by combination therapy with docetaxel and S-1]. ( Fujita, H; Fujita, J; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Ohno, Y; Tomita, Y; Ueda, N, 2013) |
"Without any sign of infection, leukocytosis developed around the 30th POD." | 2.46 | Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. ( Asada, Y; Fujisawa, K; Iida, Y; Kawaguchi, M; Mitsui, T; Miura, S; Munemoto, Y; Sudo, Y; Takehara, A; Terada, T, 2010) |
"We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy." | 1.72 | Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. ( Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H, 2022) |
"This was a real-world study of gastric cancer patients with peritoneal metastasis who have been treated with AS or SOX regimen as first-line chemotherapy." | 1.72 | Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study. ( Cui, Y; Li, Q; Li, W; Liu, T; Wang, Y; Yu, S; Yu, Y; Zhang, J; Zhang, L, 2022) |
"We report a case of advanced gastric cancer with peritoneal metastasis achieved pathological complete response by chemotherapy." | 1.56 | [A Case of Advanced Gastric Cancer with Peritoneal Metastasis Achieved Pathological Complete Response by Chemotherapy(SOX Regimen)]. ( Danno, K; Ikeda, K; Kawagishi, S; Nishigaki, T; Oka, Y; Sugimoto, K; Takahashi, K; Takeyama, H; Taniguchi, H; Tokunaga, T; Toyoda, Y; Yamamoto, H; Yamashita, M, 2020) |
" She underwent chemotherapy comprisingintravenous and intraperitoneal paclitaxel combined with S-1." | 1.51 | [A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy]. ( Amano, S; Goto, A; Hanai, T; Hattori, Y; Inaba, K; Kadoya, S; Kato, Y; Kikuchi, K; Nakamura, K; Nakauchi, M; Sugioka, A; Tomatsu, M; Tsuru, Y; Uyama, I, 2019) |
"A scirrhous gastric cancer was found, and he was introduced to us." | 1.51 | [Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases]. ( Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Noma, T; Takahashi, T; Tanaka, K; Yamasaki, M, 2019) |
"Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support." | 1.51 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019) |
"A 27-year-old woman was diagnosed with gastric cancer complicated peritoneal dissemination and direct invasion to pancreas via staging laparoscopy." | 1.48 | [Advanced Gastric Cancer with Peritoneal Dissemination Treated with Conversion Surgery after S-1 and CDDP Chemotherapy - A Case Report]. ( Hasegawa, H; Kakeji, Y; Kanaji, S; Matsuda, T; Matsuda, Y; Nakamura, T; Oshikiri, T; Sumi, Y; Suzuki, S; Ueta, K; Yamamoto, M; Yamashita, K, 2018) |
"In the latest Japanese gastric cancer treatment guidelines, PAM plus paclitaxel(PTX)was positioned as a second-line chemotherapy for advanced gastric cancer." | 1.48 | [A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel]. ( Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T, 2018) |
"A 58-year-old man was diagnosed with gastric cancer in 2006." | 1.48 | [A Case of Peritoneal Dissemination of Metastatic Gastric Cancer with Successful Docetaxel and S-1 Combination Therapy]. ( Fujiwara, A; Hama, N; Hamakawa, T; Hirao, M; Kato, S; Kato, T; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takami, K; Uemura, M, 2018) |
"The outcome of gastric cancer patients with peritoneal metastasis remains poor." | 1.46 | Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis. ( Ishigami, H; Kitayama, J; Kurihara, M; Satoh, Y; Yamaguchi, H; Yatomi, Y, 2017) |
"We report herein a rare case of gastric cancer with peritoneal dissemination who achieved 5- year survival after surgery along with the literature review." | 1.43 | [A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel]. ( Kakiuchi, Y; Takashima, H; Urano, S, 2016) |
"Advanced sigmoid colon cancer with stenosis was discovered in a man in his 50's who presented with constipation." | 1.43 | [Pathological Complete Response to SOX plus Bevacizumab for Treating Stage IV Sigmoid Colon Cancer]. ( Emi, M; Hirabayashi, N; Ibuki, Y; Kagimoto, A; Kaneko, M; Mukaida, H; Takiyama, W; Yoshimitsu, M, 2016) |
"Paclitaxel (PTX) was administered via an IP access port implanted in the subcutaneous space." | 1.42 | Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. ( Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H, 2015) |
"Among 790 gastric cancer patients between 2005 and 2009, 52 cases of CY1 were identified (6." | 1.42 | Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test. ( Hoshi, K; Hosoda, K; Katada, N; Kikuchi, S; Mieno, H; Moriya, H; Ushiku, H; Watanabe, M; Yamashita, K, 2015) |
"The standard treatment of gastric cancer patients with PD is combination therapy with S-1 and cisplatin (SP therapy)." | 1.42 | [S-1 plus Cisplatin Combination Therapy for Gastric Cancer with Peritoneal Dissemination]. ( Akita, H; Fujiwara, Y; Gotoh, K; Hara, T; Kobayashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2015) |
"Treatment of the endometrial cancer with cytoreductive surgery followed by adjuvant chemotherapy was performed first." | 1.42 | [A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis]. ( Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Sasaki, K; Souda, H; Takiguchi, N; Tonooka, T; Yamamoto, H, 2015) |
"Here, we report 2 patients with gastric cancer and peritoneal dissemination who were successfully treated with chemotherapy after undergoing treatment for an oncologic emergency caused by peritoneal dissemination." | 1.42 | [Introduction of Chemotherapy for Advanced Gastric Cancer Showing Oncologic Emergency Caused by Peritoneal Dissemination--Report of Tow Cases]. ( Akita, H; Fujiwara, Y; Gotoh, K; Kobayashi, S; Miyata, H; Miyoshi, N; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2015) |
"Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 1.40 | Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. ( Fuse, N; Goto, M; Hamaguchi, T; Ito, S; Katai, H; Konishi, M; Sano, T; Sasako, M; Shirao, K; Takahari, D; Tanigawa, N; Terashima, M; Yasui, H; Yoshimura, K, 2014) |
"Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes." | 1.40 | Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. ( Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2014) |
"Management of peritoneal disseminated gastric cancer (GC) remains a challenging problem." | 1.40 | Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. ( Canbay, E; Hirano, M; Ichinose, M; Ishibashi, H; Mizumoto, A; Sako, S; Takao, N; Yonemura, Y, 2014) |
"Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
"Here we report a case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy." | 1.40 | [A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy]. ( Aisu, N; Hoshino, S; Maki, K; Naito, M; Nakagawa, M; Yamashita, Y; Yoshida, Y, 2014) |
" The goal of this study was to evaluate the efficacy and safety of combination therapy of cetuximab and S-1 combined with oxaliplatin (SOX) in Chinese patients with advanced gastric cancer." | 1.40 | Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. ( Chen, XB; Hua, YW; Kong, Y; Liu, HX; Ma, EM; Yang, W; Zhang, B; Zhang, YL; Zhang, ZD, 2014) |
"Gastric adenosquamous carcinoma is a rare malignancy with a poor prognosis." | 1.40 | [A case of gastric adenosquamous carcinoma with peritoneal dissemination in which treatment with S-1 plus paclitaxel therapy resulted in improved long-term survival]. ( Hirano, M; Ichinose, M; Mizumoto, A; Ozamoto, Y; Takao, N; Tatsuno, M; Togawa, T; Yamamoto, Y; Yonemura, Y, 2014) |
"We report a case of gastric cancer with peritoneal dissemination that was successfully treated with low-dose S-1 or capecitabine chemotherapy over a 5-year period." | 1.40 | [A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years]. ( Hara, Y; Minami, Y; Nakamura, T; Ueda, S, 2014) |
"We report a case of advanced gastric cancer that was successfully treated with second-line chemotherapy followed by curative conversion gastrectomy." | 1.40 | [A case of advanced gastric cancer successfully treated with second-line chemotherapy followed by curative conversion gastrectomy]. ( Asaoka, T; Endo, S; Fujitani, K; Fukuda, Y; Fukui, A; Fushimi, H; Harada, Y; Haraguchi, N; Hirao, M; Ikeda, M; Iwase, K; Kawada, J; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takagi, M; Yamamoto, K, 2014) |
"A gastric cancer recurrence with paraaortic lymph node (PALN) metastasis was diagnosed fifteen months after the operation." | 1.40 | [A case of successful treatment of peritoneal dissemination from gastric cancer with S-1/DOC chemotherapy]. ( Ebisui, C; Fukuchi, N; Kinuta, M; Murata, K; Nushijima, Y; Okada, K; Okamura, S; Yanagisawa, T; Yokouchi, H, 2014) |
"A 35-year-old female with scirrhous stomach cancer (stage IV) was treated with a combination of 5-aminolevulinic acid (ALA), sodium dichloroacetate (DCA), hyperthermotherapy, and immunotherapy as terminal care." | 1.39 | A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). ( Goto, S; Kamigaki, T; Saito, M; Yano, K, 2013) |
"AFP-producing gastric cancer with peritoneal metastasis has a poor prognosis, but chemotherapy, mainly with S-1 and trastuzumab, was effective for it." | 1.39 | [A case of AFP-producing gastric cancer with peritoneal metastasis treated effectively with chemotherapy, mainly using S-1 and trastuzumab]. ( Ishikawa, H; Ishioka, K; Ko, S; Matsusaka, M; Mukogawa, T; Nishiwada, S; Watanabe, A; Yoshikawa, T, 2013) |
"Twenty-eight patients with advanced gastric cancer underwent gastrectomy without preoperative chemotherapy." | 1.39 | Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery. ( Fujita, I; Kanazawa, Y; Kato, S; Onodera, H; Uchida, E, 2013) |
"He survived without recurrence for approximately 2 years after gastrectomy." | 1.39 | [A case of advanced gastric cancer with peritoneal dissemination recurrence after gastrectomy effectively treated with combination chemotherapy of S-1 and docetaxel]. ( Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Okada, K; Okamura, S; Takeoka, T; Wada, Y; Yanagisawa, T; Yokouchi, H, 2013) |
"Rectal stenosis was improved and complete remission was maintained until May 2013." | 1.39 | [A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy]. ( Cho, H; Fujikawa, H; Iwasaki, K; Kasahara, A; Masuda, M; Ogata, T; Osaragi, T; Rino, Y; Shirai, J; Sujishi, K; Tsuburaya, A; Yamada, T; Yamamoto, Y; Yoneyama, K; Yoshikawa, T, 2013) |
" Two cycles of intraperitoneal chemotherapy with docetaxel combined with S-1, were administrated and gastrectomy with lymph node dissection was performed in cases without macroscopic PC at post-NIPS staging laparoscopy." | 1.38 | Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. ( Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2012) |
"We report two cases of advanced gastric cancer." | 1.38 | [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel]. ( Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S, 2012) |
"A 59-year-old man with type 3 gastric cancer(signet-ring cell carcinoma)underwent simple laparotomy because of peritoneal dissemination." | 1.38 | [A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment]. ( Goto, M; Hirata, Y; Kawahara, Y; Kitamura, M; Nakayama, M; Ohta, R; Oneyama, M; Sekikawa, K; Shimoda, Y; Takahashi, Y, 2012) |
"We report a gastric cancer patient with positive peritoneal lavage cytology (CY1) who achieved 20-month progression free survival by S-1 monotherapy." | 1.38 | [S-1 monotherapy achieved twenty-month survival for peritoneal lavage cytology-positive gastric cancer patient undergoing noncurative resection]. ( Kiyokawa, T; Nishida, M; Seto, Y; Shimoyama, S, 2012) |
"Borrmann-type 3 gastric cancer with hemorrhaging was revealed by stomach endoscopy." | 1.37 | [A case of gastric cancer with peritoneal dissemination successfully treated by S-1/paclitaxel combination chemotherapy]. ( Shoji, T, 2011) |
"Gluteal recurrence of the original gastric cancer was suggested, and systemic chemotherapy consisting of S-1 at 100 mg/day (3 weeks on, 1 week off) and CDDP (day 8) was started." | 1.37 | Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination. ( Deguchi, R; Iwata, Y; Mine, T; Numata, M; Ogasawara, F; Ohtani, Y; Sakuma, T; Sato, S; Takashimizu, S, 2011) |
" We judged that curative resection was impossible and finished the operation after giving an intra-abdominal dosage of cisplatin(CDDP)at 85mg." | 1.37 | [A case of gastric carcinoma with peritoneal metastasis successfully treated by combination chemotherapy of S-1 and cisplatin]. ( Gon, H; Ishida, T; Iwasaki, T; Kanemitsu, K; Nakajima, T; Okuda, T; Tanaka, K; Toyokawa, A; Yamashita, H, 2011) |
"We report two cases of advanced gastric cancer successfully treated with combination S-1 and docetaxel (DOC) therapy." | 1.36 | [Two cases of advanced gastric cancer with peritoneal dissemination, and Virchow's metastases successfully treated by combination therapy of S-1 and docetaxel]. ( Hasegawa, H; Kijima, T; Kitahara, M; Kubo, H; Miyahara, M; Tada, K, 2010) |
"Paclitaxel 50mg/m2 was administered on days 1 and 8." | 1.36 | [Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)]. ( Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H, 2010) |
" Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites." | 1.36 | Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
"In advanced gastric cancer with peritoneal metastasis, adjuvant chemotherapy after primary tumor resection showed considerably poor prognosis with a median survival time of only 232 days." | 1.36 | [Strategy of treatment for gastric cancer with peritoneal metastasis]. ( Adachi, T; Hatoh, T; Matsui, K; Oshita, H; Tanemura, H; Yamada, M, 2010) |
"Paclitaxel was administered at 120 mg/m(2) on day 1 and S-1 was administered orally at 80 mg/m(2) for 14 consecutive days, followed by a 1-week rest, as one course." | 1.36 | Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer. ( Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Uji, K; Yoshida, A, 2010) |
"No re-growth of gastric cancer has been seen for 9 months with this chemotherapy." | 1.36 | [A very elderly case of recurrent gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of docetaxel (DOC) and S-1]. ( Hachisuka, T; Hattori, K; Kinoshita, T; Miyauchi, M; Mori, T; Shikano, T; Shinohara, M; Yamamoto, T, 2010) |
"A 75-year-old man with advanced gastric cancer underwent distal gastrectomy with lymph node dissection(D1)and Roux-en Y reconstruction." | 1.35 | [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy]. ( Arai, H; Kashiwabara, M; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Mizutani, T; Nishi, Y; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T, 2008) |
"They were diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy, or with metastasis to the transverse colon." | 1.35 | Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer. ( Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Yoshimura, M, 2008) |
"The patient was diagnosed with typeIII gastric cancer by gastroendoscopy postoperatively." | 1.35 | [A case of perforated gastric cancer in which resection for elimination was possible S-1/CDDP combined chemotherapy for peritonitis carcinomatosa]. ( Itakura, T; Sugimoto, T; Uesaka, K, 2009) |
"Two unresectable advanced gastric cancer cases with peritoneal metastases were successfully treated by the combination therapy of S-1 and paclitaxel." | 1.35 | [Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy]. ( Ando, T; Furuta, R; Goto, H; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Nagao, S; Nishio, T, 2009) |
"Abdominal CT scan revealed pancreatic cancer with massive ascites showing peritoneal dissemination, combined with lymph node and liver metastases." | 1.35 | [A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases]. ( Fushida, S; Kimura, H; Mukawa, A, 2009) |
"We encountered a patient with gastric cancer demonstrating peritoneal dissemination, who was successfully treated by combination therapy using S-1 and docetaxel." | 1.35 | [A case of gastric cancer with peritoneal dissemination-efficacy of combination therapy with S-1 and docetaxel]. ( Futagawa, S; Kitajima, M; Konishi, N; Marusasa, T; Nishimura, K; Ochiai, T; Satoh, G; Watanabe, T, 2009) |
"The prognosis of gastric cancer patients with peritoneal dissemination is poor." | 1.35 | Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. ( Hosogi, H; Obama, K; Okabe, H; Sakai, Y; Ueda, S, 2009) |
"The subjects were type 4 advanced gastric cancer cases from October 2002 to December 2007 who underwent st-lap, as well as 7 P0 and CY0 [P(-)] cases (the operative group), and 18 P(+) cases which underwent chemotherapy (the chemotherapy group)." | 1.35 | [Outcome of therapy for type 4 gastric cancer with peritoneal metastasis--diagnosis by laparoscopy and effect of chemotherapy]. ( Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M; Yoshioka, Y, 2009) |
"Most gastric cancer patients with peritoneal dissemination die within a few months, and there is no standard treatment for peritoneal dissemination from gastric cancer." | 1.35 | [A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy]. ( Asami, S; Hirata, M; Idani, H; Kin, H; Kubo, S; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yamashita, T; Yoshioka, T, 2009) |
"Gemcitabine (1,000 mg/m2) was intravenously administered 3 times (on days 1, 8, 15) every 4 weeks (days 1-28) as 1 course." | 1.35 | [A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer]. ( Egawa, T; Hayashi, S; Ito, Y; Mihara, K; Nagashima, A; Ohashi, M; Takahashi, T, 2009) |
"We report a case of gastric cancer with ascites treated with chemotherapy." | 1.34 | [Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel]. ( Arakawa, T; Fujii, K; Kaneda, K; Kawamura, C; Kayo, S; Mizuyama, Y; Nakagawa, H; Ueda, Y; Uno, H, 2007) |
"In general, treatment for gastric cancer with peritoneal dissemination or recurrent gastric cancer is outside the scope of surgery." | 1.33 | [A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL]. ( Kawasaki, H; Kobori, H; Maruyama, M; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Yamada, K, 2005) |
"She was diagnosed as remnant gastric cancer with multiple bone metastasis and peritoneal dissemination." | 1.33 | [A case of remnant gastric cancer with multiple bone metastasis and peritoneal dissemination; efficacy of combination therapy of docetaxel and TS-1]. ( Hamai, Y; Hihara, J; Tanabe, K; Toge, T; Ukon, K; Yoshida, K, 2005) |
"One case with type 4 gastric cancer who had right hydronephrosis and malignant abdominal ascites underwent curative resection after successful treatment with TS-1." | 1.33 | [Peritoneal dissemination of scirrhous type 4 gastric cancers]. ( Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S, 2005) |
"In advanced gastric cancer, the frequency of relapses such as metastasis to the peritoneum is high." | 1.33 | [Prediction and treatment of peritoneal dissemination in gastric cancer]. ( Aratake, K; Itabashi, M; Kameoka, S; Mitsuhashi, M; Ogawa, S; Seshimo, A; Shirotani, N, 2005) |
"We reported 2 cases with advanced gastric cancer, successfully treated with TS-1 and CDDP." | 1.33 | [Two cases of advanced gastric cancer, successfully treated with TS-1/CDDP combination chemotherapy--case report]. ( Ando, K; Ishihara, C; Ishiwa, N; Morinaga, S; Noguchi, Y; Ogoshi, T; Shotsu, M; Takeda, A; Yamamoto, Y; Yoshida, S; Yoshikawa, T, 2005) |
" There were less severe adverse events concerning paclitaxel despite of the second line therapy of TS-1, and 80 percent of all therapeutic courses was at an outpatient clinic." | 1.33 | [Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination]. ( Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K, 2005) |
"By a diagnosis of descending colon cancer, descending colon ablative operation and D1 lymph node dissection were performed on April 22, 2004." | 1.33 | [A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy]. ( Fujishima, M; Fukunaga, M; Furukawa, H; Imamura, H; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Ooshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K, 2005) |
"Paclitaxel was ineffective, and so we opted for weekly administration of low-dose CDDP combined with TS-1, which led to the third recovery." | 1.33 | [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs]. ( Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2006) |
"Upper GI endoscopy revealed type 3 gastric cancer from the anglus to the cardia." | 1.33 | [A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL]. ( Kimura, H; Koyama, F, 2006) |
"We report a case of gastric cancer with peritoneal recurrence that responded to chemotherapy with paclitaxel and TS-1." | 1.33 | [A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1]. ( Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2006) |
"The response of gastric cancer with peritoneal dissemination to systemic chemotherapy may be negatively affected by poor drug delivery due to the blood-peritoneal barrier." | 1.33 | Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. ( Hatori, S; Imada, T; Kunisaki, C; Oshima, T; Yamada, R, 2006) |
"Further examination showed an advanced gastric cancer with peritoneal dissemination." | 1.33 | [A case of advanced gastric cancer with peritoneal dissemination responding remarkably to TS-1/CDDP combination chemotherapy]. ( Asagoe, K; Azechi, H; Inoue, F; Ishii, K; Katsurada, A; Kondo, M; Nishikawa, K; Nishiura, H; Nonami, M; Otani, Y; Saiga, T; Shigemori, M; Suwa, H; Tojo, M, 2006) |
"Human gastric cancer cells (MKN-45) were injected into the peritoneal cavity of nude mice." | 1.32 | Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. ( Fujiwara, Y; Monden, M; Mori, T; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T, 2003) |
"S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis." | 1.32 | Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. ( Boku, N; Doi, T; Hamamoto, Y; Kawai, H; Mera, K; Muto, M; Nagashima, F; Ohtsu, A; Sano, Y; Yano, T; Yoshida, S, 2003) |
"We treated a patient with gastric cancer considered to be unresectable due to peritoneal metastasis, who responded remarkably to treatment with TS-1." | 1.32 | [A case of peritoneal metastasis of gastric cancer responding to TS-1, administered for four consecutive weeks with two-week rests]. ( Adachi, I; Emoto, T; Fujii, M; Fujikawa, M; Kamei, A; Komaki, T; Naka, Y; Nezu, R; Yokota, T; Yoshikawa, K; Yoshioka, Y, 2003) |
"After the 5th course, the stenosis of colon and ascites had disappeared in a barium enema and CT scan, respectively." | 1.32 | [A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1]. ( Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H, 2003) |
"An umbilical metastasis of gastric cancer is known as Sister Mary Joseph's nodule." | 1.32 | [A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum]. ( Fukunaga, S; Hirakawa, K; Inoue, T; Ishikawa, T; Kato, Y; Nakata, B; Nishiguchi, Y; Ohira, M; Takashima, T; Yamagata, S; Yashiro, M, 2004) |
"Although the prognosis of recurrent gastric cancer with peritoneal dissemination was extremely poor, this case might suggest a possibility that intensive therapies are useful in maintaining the quality of life and improving survival." | 1.32 | [A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T, 2004) |
"We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | 1.31 | [Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin]. ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 92 (42.79) | 29.6817 |
2010's | 115 (53.49) | 24.3611 |
2020's | 8 (3.72) | 2.80 |
Authors | Studies |
---|---|
Mei, Y | 1 |
Shi, M | 1 |
Zhu, Z | 2 |
Yuan, H | 1 |
Yan, C | 1 |
Li, C | 1 |
Feng, T | 1 |
Yan, M | 1 |
Zhang, J | 2 |
Todaka, A | 1 |
Nara, S | 1 |
Motoi, F | 2 |
Morinaga, S | 2 |
Toshiyama, R | 1 |
Higuchi, R | 1 |
Konishi, M | 2 |
Shirakawa, H | 1 |
Tsumura, H | 1 |
Okuyama, H | 1 |
Nagano, H | 1 |
Shioji, K | 1 |
Sugimachi, K | 1 |
Asagi, A | 1 |
Mizuno, N | 1 |
Furuse, J | 1 |
Zhang, L | 1 |
Wang, Y | 2 |
Li, W | 1 |
Yu, S | 1 |
Li, Q | 2 |
Yu, Y | 2 |
Liu, T | 2 |
Cui, Y | 2 |
Kobayashi, D | 1 |
Ishigami, H | 14 |
Kanda, M | 1 |
Tanaka, C | 1 |
Yamaguchi, H | 8 |
Kitayama, J | 13 |
Kodera, Y | 5 |
Yamaguchi, T | 4 |
Takashima, A | 1 |
Nagashima, K | 1 |
Makuuchi, R | 1 |
Aizawa, M | 1 |
Ohashi, M | 6 |
Tashiro, K | 1 |
Yamada, T | 4 |
Kinoshita, T | 2 |
Hata, H | 1 |
Kawachi, Y | 1 |
Kawabata, R | 1 |
Tsuji, T | 1 |
Hihara, J | 2 |
Sakamoto, T | 1 |
Fukagawa, T | 1 |
Katai, H | 3 |
Higuchi, K | 1 |
Boku, N | 7 |
Naruse, T | 1 |
Hirono, Y | 3 |
Kurebayashi, H | 1 |
Katayama, H | 2 |
Sawai, K | 1 |
Morikawa, M | 1 |
Koneri, K | 1 |
Tamaki, M | 1 |
Murakami, M | 3 |
Goi, T | 1 |
Nakamura, M | 2 |
Ojima, T | 1 |
Katsuda, M | 1 |
Hayata, K | 1 |
Kitadani, J | 1 |
Nakamori, M | 2 |
Yamaue, H | 2 |
Nishigaki, T | 2 |
Oka, Y | 2 |
Taniguchi, H | 1 |
Takahashi, K | 6 |
Kawagishi, S | 1 |
Yamashita, M | 1 |
Takeyama, H | 1 |
Danno, K | 1 |
Toyoda, Y | 1 |
Tokunaga, T | 1 |
Sugimoto, K | 10 |
Yamamoto, H | 2 |
Ikeda, K | 2 |
Kano, K | 1 |
Aoyama, T | 3 |
Maezawa, Y | 1 |
Nakajima, T | 4 |
Sato, T | 2 |
Oshima, T | 3 |
Rino, Y | 4 |
Masuda, M | 4 |
Ogata, T | 5 |
Cho, H | 7 |
Yoshikawa, T | 11 |
Satoh, Y | 1 |
Kurihara, M | 1 |
Yatomi, Y | 1 |
Nakayama, I | 1 |
Chin, K | 2 |
Matsushima, T | 1 |
Takahari, D | 4 |
Ogura, M | 1 |
Shinozaki, E | 1 |
Suenaga, M | 1 |
Ozaka, M | 1 |
Wakatsuki, T | 1 |
Ichimura, T | 1 |
Hiroki, O | 1 |
Yamaguchi, K | 5 |
Shimaoka, H | 1 |
Shibata, R | 1 |
Hosoda, Y | 1 |
Hirano, Y | 1 |
Munechika, T | 1 |
Yonemitsu, K | 1 |
Ishii, Y | 2 |
Okamoto, T | 1 |
Maeno, H | 1 |
Noritomi, T | 1 |
Yoshida, T | 3 |
Sueishi, K | 1 |
Miura, S | 2 |
Ueda, N | 2 |
Fujita, H | 2 |
Kinami, S | 2 |
Nakano, Y | 2 |
Kosaka, T | 2 |
Sakata, N | 1 |
Nishino, R | 1 |
Shimomura, K | 2 |
Furuke, Y | 1 |
Tanaka, Y | 2 |
Kumano, T | 1 |
Komatsu, S | 1 |
Imura, K | 1 |
Ikeda, J | 2 |
Taniguchi, F | 2 |
Shioaki, Y | 2 |
Nakatsugawa, Y | 1 |
Matsuda, Y | 1 |
Nakamura, T | 3 |
Ueta, K | 1 |
Hasegawa, H | 2 |
Yamamoto, M | 7 |
Kanaji, S | 1 |
Yamashita, K | 2 |
Oshikiri, T | 1 |
Matsuda, T | 1 |
Sumi, Y | 1 |
Suzuki, S | 2 |
Kakeji, Y | 1 |
Shinkai, M | 3 |
Imano, M | 5 |
Chiba, Y | 2 |
Hiraki, Y | 2 |
Kato, H | 3 |
Iwama, M | 2 |
Shiraisi, O | 1 |
Yasuda, A | 3 |
Tsubaki, M | 3 |
Nishida, S | 3 |
Kimura, Y | 5 |
Yasuda, T | 6 |
Shiraishi, O | 1 |
Saito, K | 2 |
Isayama, H | 4 |
Nakai, Y | 3 |
Takahara, N | 2 |
Ishigaki, K | 1 |
Takeda, T | 1 |
Hakuta, R | 1 |
Saito, T | 1 |
Uchino, R | 1 |
Kishikawa, T | 1 |
Hamada, T | 1 |
Mizuno, S | 1 |
Sasaki, T | 4 |
Kogure, H | 3 |
Matsubara, S | 1 |
Yamamoto, N | 2 |
Ijichi, H | 2 |
Tateishi, K | 2 |
Tada, M | 3 |
Koike, K | 3 |
Muroya, T | 1 |
Wajima, N | 1 |
Kubo, N | 2 |
Yoshida, E | 1 |
Akaishi, T | 1 |
Umetsu, S | 1 |
Wakasa, Y | 1 |
Sato, K | 1 |
Mitsuhashi, Y | 1 |
Umemura, K | 1 |
Ogasawara, H | 1 |
Hara, Y | 2 |
Hakamada, K | 1 |
Okada, K | 12 |
Kawanaka, S | 1 |
Taniguchi, S | 1 |
Adachi, S | 1 |
Yoshioka, S | 1 |
Ueshima, S | 2 |
Higaki, N | 1 |
Hayashida, H | 1 |
Nezu, R | 2 |
Kato, S | 2 |
Nishikawa, K | 5 |
Hirao, M | 3 |
Hamakawa, T | 2 |
Fujiwara, A | 1 |
Maeda, S | 2 |
Uemura, M | 1 |
Miyake, M | 2 |
Hama, N | 1 |
Miyamoto, A | 2 |
Miyazaki, M | 3 |
Kato, T | 3 |
Takami, K | 1 |
Nakamori, S | 2 |
Sekimoto, M | 2 |
Hattori, Y | 1 |
Nakauchi, M | 1 |
Tsuru, Y | 1 |
Amano, S | 1 |
Goto, A | 1 |
Tomatsu, M | 1 |
Nakamura, K | 3 |
Kikuchi, K | 1 |
Kadoya, S | 1 |
Inaba, K | 1 |
Kato, Y | 2 |
Hanai, T | 1 |
Sugioka, A | 1 |
Uyama, I | 1 |
Noma, T | 1 |
Takahashi, T | 7 |
Miyazaki, Y | 2 |
Kurokawa, Y | 4 |
Tanaka, K | 4 |
Makino, T | 1 |
Nakajima, K | 6 |
Yamasaki, M | 5 |
Mori, M | 5 |
Doki, Y | 7 |
Terashima, M | 3 |
Iwasaki, Y | 5 |
Mizusawa, J | 2 |
Ito, Y | 5 |
Kaji, M | 3 |
Yamada, M | 2 |
Kurita, A | 2 |
Takagi, M | 2 |
Sano, T | 2 |
Sasako, M | 2 |
Arai, H | 2 |
Iwasa, S | 1 |
Kawahira, M | 1 |
Yasui, H | 5 |
Masuishi, T | 1 |
Muro, K | 4 |
Minashi, K | 2 |
Hironaka, S | 3 |
Fukuda, N | 1 |
Nakajima, TE | 1 |
Fushida, S | 3 |
Kinoshita, J | 1 |
Goda, F | 4 |
Yagi, Y | 3 |
Oyama, K | 2 |
Sudo, Y | 2 |
Watanabe, Y | 2 |
Fujimura, T | 2 |
Hamaguchi, T | 1 |
Yoshimura, K | 1 |
Ito, S | 4 |
Fuse, N | 2 |
Goto, M | 3 |
Tanigawa, N | 1 |
Shirao, K | 2 |
Saito, M | 1 |
Yano, K | 1 |
Kamigaki, T | 1 |
Goto, S | 1 |
Emoto, S | 5 |
Yamashita, H | 8 |
Watanabe, T | 5 |
Nishiwada, S | 1 |
Watanabe, A | 1 |
Ishioka, K | 1 |
Mukogawa, T | 1 |
Matsusaka, M | 1 |
Ko, S | 1 |
Ishikawa, H | 2 |
Katayama, K | 1 |
Nishino, T | 1 |
Takahashi, Y | 2 |
Tanaka, T | 4 |
Okitsu, H | 1 |
Okitsu, N | 1 |
Kaisaki, S | 5 |
Watanabe, K | 2 |
Kawahara, H | 2 |
Enomoto, H | 2 |
Toyama, Y | 1 |
Akiba, T | 2 |
Yanaga, K | 2 |
Nemoto, H | 1 |
Uchiyama, M | 1 |
Atsumi, Y | 1 |
Hasegawa, S | 2 |
Tamagawa, H | 1 |
Yukawa, N | 1 |
Imada, T | 3 |
Kanazawa, Y | 1 |
Fujita, I | 1 |
Onodera, H | 1 |
Uchida, E | 1 |
Canbay, E | 2 |
Mizumoto, A | 3 |
Ichinose, M | 2 |
Ishibashi, H | 2 |
Sako, S | 1 |
Hirano, M | 2 |
Takao, N | 2 |
Yonemura, Y | 4 |
Ohnishi, T | 1 |
Fujita, J | 1 |
Morioka, E | 1 |
Kaida, D | 1 |
Ohno, Y | 1 |
Tomita, Y | 1 |
Noguchi, M | 1 |
Funaki, H | 1 |
Shirai, J | 2 |
Fujikawa, H | 2 |
Iwasaki, K | 2 |
Tsuburaya, A | 8 |
Sujishi, K | 2 |
Osaragi, T | 2 |
Yoneyama, K | 2 |
Kasahara, A | 2 |
Yamamoto, Y | 5 |
Wada, Y | 2 |
Ebisui, C | 4 |
Kato, R | 2 |
Makino, S | 2 |
Takeoka, T | 1 |
Yanagisawa, T | 3 |
Okamura, S | 10 |
Fukuchi, N | 3 |
Murata, K | 3 |
Yokouchi, H | 3 |
Kinuta, M | 3 |
Sasaki, K | 2 |
Fujiwara, Y | 12 |
Kishi, K | 1 |
Motoori, M | 2 |
Sugimura, K | 3 |
Miyoshi, N | 3 |
Akita, H | 3 |
Gotoh, K | 3 |
Takahashi, H | 4 |
Marubashi, S | 1 |
Noura, S | 3 |
Ohue, M | 3 |
Yano, M | 6 |
Sakon, M | 3 |
Tomoda, M | 1 |
Hayashi, T | 3 |
Tanabe, K | 2 |
Morita, S | 2 |
Miyashita, Y | 1 |
Sakamoto, J | 1 |
Naito, M | 1 |
Aisu, N | 1 |
Maki, K | 1 |
Nakagawa, M | 1 |
Yoshida, Y | 1 |
Hoshino, S | 1 |
Yamashita, Y | 3 |
Zhang, ZD | 1 |
Kong, Y | 1 |
Yang, W | 1 |
Zhang, B | 1 |
Zhang, YL | 1 |
Ma, EM | 1 |
Liu, HX | 1 |
Chen, XB | 1 |
Hua, YW | 1 |
Koga, H | 1 |
Miyoshi, A | 1 |
Nakamura, J | 1 |
Ide, T | 1 |
Kitahara, K | 1 |
Noshiro, H | 1 |
Yamamura, A | 1 |
Ono, F | 1 |
Hiraga, M | 1 |
Omura, N | 1 |
Takano, N | 1 |
Sato, H | 1 |
Toyama, S | 1 |
Onochi, S | 1 |
Ozamoto, Y | 1 |
Togawa, T | 1 |
Tatsuno, M | 1 |
Ueda, S | 3 |
Minami, Y | 1 |
Osaki, T | 1 |
Kuroda, H | 1 |
Nagai, S | 1 |
Watanabe, H | 1 |
Takahashi, S | 2 |
Kurisu, Y | 1 |
Ikeguchi, M | 1 |
Shiozaki, S | 1 |
Satoh, D | 1 |
Matsukawa, H | 1 |
Mimura, N | 1 |
Taguchi, K | 1 |
Araki, H | 1 |
Toshima, T | 1 |
Miyake, S | 1 |
Miyoshi, H | 1 |
Yoshida, K | 2 |
Choda, Y | 1 |
Tokumoto, N | 1 |
Kanazawa, T | 1 |
Harano, M | 1 |
Ojima, Y | 1 |
Idani, H | 2 |
Okajima, M | 1 |
Ninomiya, M | 2 |
Tsukamoto, T | 2 |
Kanazawa, A | 1 |
Shimizu, S | 2 |
Sakae, M | 1 |
Ohira, G | 1 |
Yoshii, M | 1 |
Ishikawa, A | 1 |
Mori, Y | 2 |
Kotsuka, M | 1 |
Goto, W | 1 |
Kurihara, S | 1 |
Tashima, T | 1 |
Deguchi, S | 1 |
Tachimori, A | 1 |
Tamamori, Y | 1 |
Yamamoto, A | 1 |
Inoue, T | 3 |
Nishiguchi, Y | 2 |
Kawada, J | 1 |
Fujitani, K | 3 |
Yamamoto, K | 4 |
Fukui, A | 1 |
Fushimi, H | 1 |
Endo, S | 1 |
Iwase, K | 2 |
Harada, Y | 1 |
Fukuda, Y | 1 |
Haraguchi, N | 1 |
Asaoka, T | 1 |
Ikeda, M | 1 |
Nushijima, Y | 1 |
Iwai, N | 1 |
Wakabayashi, N | 1 |
Matsumoto, N | 1 |
Morita, Y | 1 |
Tanaka, N | 3 |
Yoriki, H | 1 |
Fujii, K | 2 |
Takada, R | 1 |
Takaya, H | 1 |
Masuzawa, A | 1 |
Takami, S | 1 |
Kataoka, K | 1 |
Kurahashi, S | 1 |
Misawa, K | 1 |
Niwa, Y | 2 |
Yatabe, Y | 1 |
Shimizu, Y | 2 |
Miyata, H | 7 |
Takiguchi, S | 9 |
Ito, T | 1 |
Hanafusa, N | 1 |
Ushiku, H | 1 |
Katada, N | 1 |
Hosoda, K | 1 |
Moriya, H | 1 |
Mieno, H | 1 |
Kikuchi, S | 2 |
Hoshi, K | 1 |
Watanabe, M | 1 |
Nishina, T | 2 |
Gotoh, M | 3 |
Shimada, Y | 1 |
Hamamoto, Y | 2 |
Kawai, H | 2 |
Nakayama, N | 1 |
Amagai, K | 2 |
Ohtsu, A | 3 |
Bando, H | 1 |
Yamada, Y | 2 |
Tanabe, S | 1 |
Sugimoto, N | 1 |
Tsuji, A | 2 |
Imamura, H | 3 |
Tsuda, M | 1 |
Fujii, H | 1 |
Shimada, K | 2 |
Miwa, H | 1 |
Hamada, C | 1 |
Hyodo, I | 1 |
Cao, C | 1 |
Kuang, M | 1 |
Xu, W | 1 |
Zhang, X | 1 |
Chen, J | 1 |
Tang, C | 1 |
Hara, T | 1 |
Omori, T | 2 |
Kobayashi, S | 2 |
Nakao, K | 1 |
Shitara, K | 4 |
Fukunari, H | 1 |
Okajima, C | 1 |
Watanabe, G | 1 |
Kobayashi, R | 1 |
Takiguchi, N | 1 |
Nabeya, Y | 1 |
Ikeda, A | 1 |
Souda, H | 1 |
Kainuma, O | 1 |
Tonooka, T | 1 |
Imanishi, S | 1 |
Arimitsu, H | 1 |
Chibana, T | 1 |
Ishige, F | 1 |
Saito, H | 2 |
Suematsu, Y | 1 |
Hiratsuka, M | 1 |
Suda, H | 1 |
Takahashi, M | 1 |
Omori, K | 1 |
Ishibashi, Y | 1 |
Morita, A | 1 |
Wakabayashi, K | 1 |
Nakade, H | 1 |
Matsumoto, S | 3 |
Wakatsuki, K | 2 |
Migita, K | 2 |
Ito, M | 2 |
Kunishige, T | 1 |
Kitano, M | 1 |
Nakatani, M | 1 |
Nakajima, Y | 2 |
Urano, S | 1 |
Kakiuchi, Y | 1 |
Takashima, H | 1 |
Li, Y | 1 |
Coccolini, F | 1 |
Glehen, O | 1 |
Sugarbaker, PH | 1 |
Morris, D | 1 |
Moran, B | 1 |
Gonzaletz-Moreno, S | 1 |
Deraco, M | 1 |
Piso, P | 1 |
Elias, D | 1 |
Batlett, D | 1 |
Verwaal, V | 1 |
Mahtem, H | 1 |
Ibuki, Y | 1 |
Yoshimitsu, M | 1 |
Emi, M | 1 |
Mukaida, H | 1 |
Hirabayashi, N | 1 |
Kagimoto, A | 1 |
Kaneko, M | 2 |
Takiyama, W | 1 |
Suzuki, K | 1 |
Yajima, K | 2 |
Yuu, K | 1 |
Oohinata, R | 1 |
Amaki, M | 1 |
Ilhan, E | 1 |
Alemdar, A | 1 |
Ureyen, O | 1 |
Bas, K | 1 |
Asakage, M | 1 |
Satoi, S | 1 |
Fujii, T | 1 |
Yanagimoto, H | 1 |
Kurata, M | 1 |
Yamada, S | 1 |
Yamamoto, T | 2 |
Mizuma, M | 1 |
Honda, G | 1 |
Unno, M | 1 |
Kon, M | 1 |
Ishiguro, T | 1 |
Fukuchi, M | 1 |
Ogura, T | 1 |
Muta, Y | 1 |
Mochiki, E | 1 |
Ishida, H | 2 |
Tokunaga, Y | 1 |
Sasaki, H | 2 |
Saitou, T | 1 |
Matsutani, T | 1 |
Mizutani, T | 1 |
Miyamoto, M | 1 |
Maruyama, H | 1 |
Yokoyama, T | 2 |
Yanagi, K | 1 |
Matsushita, A | 1 |
Kashiwabara, M | 1 |
Matsuda, A | 1 |
Nishi, Y | 1 |
Sasajima, K | 1 |
Tajiri, T | 1 |
Tokunaga, M | 1 |
Tanabe, Y | 1 |
Nasu, T | 1 |
Abe, Y | 1 |
Mitsuyama, S | 1 |
Toyoshima, S | 1 |
Ina, K | 2 |
Kataoka, T | 2 |
Takeuchi, Y | 1 |
Fukuoka, T | 1 |
Miwa, T | 1 |
Nishio, T | 2 |
Furuta, R | 2 |
Masaki, A | 2 |
Mori, F | 1 |
Kayukawa, S | 2 |
Nagao, S | 2 |
Ando, T | 2 |
Goto, H | 2 |
Lee, JL | 1 |
Kang, YK | 1 |
Kang, HJ | 1 |
Lee, KH | 1 |
Zang, DY | 1 |
Ryoo, BY | 1 |
Kim, JG | 1 |
Park, SR | 1 |
Kang, WK | 1 |
Shin, DB | 1 |
Ryu, MH | 1 |
Chang, HM | 1 |
Kim, TW | 1 |
Baek, JH | 1 |
Min, YJ | 1 |
Tanabe, D | 1 |
Kondou, K | 1 |
Uchiyama, T | 1 |
Noda, K | 1 |
Tamura, S | 11 |
Miki, H | 8 |
Miyake, T | 1 |
Yoshimura, M | 2 |
Suzuki, R | 4 |
Nakahira, S | 5 |
Nakata, K | 7 |
Takatsuka, Y | 8 |
Yamazaki, M | 2 |
Nishida, T | 3 |
Nunobe, S | 1 |
Iwanaga, T | 3 |
Iwagami, S | 1 |
Matsumoto, H | 3 |
Nakano, D | 3 |
Sugimoto, T | 1 |
Itakura, T | 1 |
Uesaka, K | 1 |
Otani, K | 3 |
Kamei, T | 3 |
Soma, D | 3 |
Miyato, H | 3 |
Hidemura, A | 3 |
Nagawa, H | 3 |
Kato, M | 2 |
Kimura, H | 2 |
Mukawa, A | 1 |
Kumagai, K | 1 |
Saikawa, Y | 3 |
Fukuda, K | 2 |
Ito, R | 1 |
Igarashi, T | 1 |
Tsuwano, S | 1 |
Nakamura, R | 3 |
Takeuchi, H | 1 |
Kitagawa, Y | 2 |
Kitajima, M | 3 |
Satoh, G | 1 |
Marusasa, T | 1 |
Konishi, N | 1 |
Ochiai, T | 2 |
Nishimura, K | 1 |
Futagawa, S | 1 |
Okabe, H | 1 |
Obama, K | 1 |
Hosogi, H | 1 |
Sakai, Y | 1 |
Seshimo, K | 1 |
Kanagawa, T | 1 |
Oishi, M | 1 |
Kodera, M | 1 |
Yamamura, M | 1 |
Katoh, H | 2 |
Ikeda, H | 1 |
Yokomichi, N | 1 |
Kobayashi, K | 1 |
Takita, K | 1 |
Koizumi, W | 1 |
Takiuchi, H | 3 |
Komatsu, Y | 1 |
Uji, K | 2 |
Yoshida, A | 2 |
Yoshioka, Y | 3 |
Egawa, C | 3 |
Asami, S | 1 |
Kubo, S | 1 |
Kurose, Y | 1 |
Nojima, H | 1 |
Yoshioka, T | 1 |
Muro, M | 1 |
Kumano, K | 1 |
Hirata, M | 1 |
Yamashita, T | 1 |
Kin, H | 1 |
Takakura, N | 1 |
Kametaka, H | 1 |
Makino, H | 1 |
Koyama, T | 1 |
Seike, K | 1 |
Egawa, T | 1 |
Mihara, K | 1 |
Hayashi, S | 2 |
Nagashima, A | 1 |
Kubo, H | 1 |
Kijima, T | 1 |
Kitahara, M | 1 |
Tada, K | 1 |
Miyahara, M | 1 |
Machida, H | 1 |
Tominaga, K | 1 |
Yano, H | 1 |
Shimokawa, T | 2 |
Tsujinaka, T | 1 |
Furukawa, H | 4 |
Murayama, Y | 1 |
Sano, I | 1 |
Doi, Y | 1 |
Iwasaki, R | 1 |
Chatani, T | 1 |
Horiki, M | 1 |
Kitada, M | 1 |
Okuno, M | 1 |
Kondo, S | 1 |
Fukuda, H | 1 |
Kashihara, T | 1 |
Kawaguchi, M | 1 |
Asada, Y | 1 |
Terada, T | 1 |
Takehara, A | 1 |
Munemoto, Y | 1 |
Fujisawa, K | 1 |
Mitsui, T | 1 |
Iida, Y | 1 |
Tanemura, H | 2 |
Oshita, H | 1 |
Hatoh, T | 1 |
Adachi, T | 1 |
Matsui, K | 1 |
Mochizuki, Y | 2 |
Kojima, T | 3 |
Nakanishi, H | 2 |
Yamamura, Y | 2 |
Sasahira, N | 2 |
Hirano, K | 2 |
Tsujino, T | 1 |
Omata, M | 1 |
Moon, JH | 1 |
Takeno, A | 2 |
Yamazaki, K | 1 |
Taku, K | 1 |
Yokota, T | 2 |
Machida, N | 1 |
Wakahara, T | 1 |
Toyokawa, A | 2 |
Tomono, A | 1 |
Tani, S | 2 |
Yamamichi, T | 1 |
Nishioka, N | 1 |
Gon, H | 2 |
Kanemitsu, K | 2 |
Okuda, T | 2 |
Hamabe, Y | 1 |
Iwasaki, T | 2 |
Ishida, T | 3 |
Akagi, T | 1 |
Etoh, T | 1 |
Eguchi, H | 1 |
Hiroishi, K | 1 |
Ueda, Y | 3 |
Yasuda, K | 1 |
Noguchi, T | 2 |
Shiraishi, N | 1 |
Kitano, S | 1 |
Shikano, T | 2 |
Hattori, K | 1 |
Hachisuka, T | 1 |
Mori, T | 4 |
Shinohara, M | 1 |
Miyauchi, M | 1 |
Sadahiro, S | 1 |
Suzuki, T | 1 |
Maeda, Y | 1 |
Tanaka, A | 1 |
Kanoda, H | 1 |
Kamijo, A | 1 |
Kanemura, T | 1 |
Yanai, A | 1 |
Kobayashi, M | 1 |
Kadono, M | 1 |
Ohinata, R | 2 |
Shoji, T | 1 |
Kurita, N | 2 |
Shimada, M | 1 |
Iwata, T | 1 |
Nishioka, M | 1 |
Morimoto, S | 1 |
Yoshikawa, K | 2 |
Higashijima, J | 1 |
Miyatani, T | 1 |
Nakao, T | 1 |
Zaima, C | 1 |
Kanai, M | 1 |
Ishikawa, S | 1 |
Kawaguchi, Y | 1 |
Masui, T | 2 |
Nishimura, T | 1 |
Yanagihara, K | 1 |
Chiba, T | 1 |
Mimori, T | 1 |
Sakuma, T | 1 |
Deguchi, R | 1 |
Takashimizu, S | 1 |
Ogasawara, F | 1 |
Numata, M | 1 |
Ohtani, Y | 1 |
Sato, S | 1 |
Mine, T | 1 |
Iwata, Y | 1 |
Masubuchi, M | 1 |
Matsumura, T | 1 |
Oomoto, K | 1 |
Horiba, T | 1 |
Sato, E | 1 |
Orihara, A | 1 |
Sonoda, H | 1 |
Hamada, J | 1 |
Itokawa, Y | 1 |
Ueshima, Y | 1 |
Takashina, K | 1 |
Lee, C | 1 |
Kuwabara, H | 1 |
Mikayama, Y | 1 |
Kitasato, Y | 1 |
Yasunaga, M | 1 |
Nakayama, M | 2 |
Akasu, G | 1 |
Yoshitomi, M | 1 |
Mikagi, K | 1 |
Kawahara, R | 1 |
Hisaka, T | 1 |
Horiuchi, H | 1 |
Kinoshita, H | 1 |
Okabe, Y | 1 |
Narita, T | 1 |
Suzuki, A | 2 |
Hashizume, E | 1 |
Yajima, M | 1 |
Mizota, A | 1 |
Matsuo, K | 1 |
Sato, Y | 1 |
Kondo, C | 1 |
Ura, T | 1 |
Tajika, M | 1 |
Okumura, K | 1 |
Shiogai, Y | 1 |
Kodama, M | 1 |
Mekata, E | 1 |
Tan, T | 1 |
Enomoto, K | 1 |
Takayama, T | 1 |
Ohno, T | 1 |
Horiguchi, N | 1 |
Asukai, K | 1 |
Miura, A | 1 |
Koguchi, H | 1 |
Matsunaga, S | 1 |
Togawa, S | 1 |
Hasegawa, I | 1 |
Sakakibara, K | 1 |
Oneyama, M | 1 |
Sekikawa, K | 1 |
Kitamura, M | 1 |
Kawahara, Y | 1 |
Ohta, R | 1 |
Hirata, Y | 1 |
Shimoda, Y | 1 |
Kawakubo, K | 1 |
Iwakura, S | 1 |
Shimamoto, T | 1 |
Higashiguchi, T | 1 |
Nakase, T | 1 |
Kunimoto, H | 1 |
Aoki, Y | 1 |
Peng, YF | 1 |
Itoh, T | 1 |
Nishikawa, M | 1 |
Satou, T | 1 |
Inoue, K | 1 |
Imamoto, H | 2 |
Takeyama, Y | 1 |
Okuno, K | 1 |
Shiozaki, H | 1 |
Shimoyama, S | 1 |
Kiyokawa, T | 1 |
Nishida, M | 1 |
Seto, Y | 1 |
Chen, Y | 1 |
Feng, Y | 1 |
Muguruma, K | 1 |
Tanaka, H | 1 |
Sakurai, K | 1 |
Kimura, K | 1 |
Nagahara, H | 1 |
Amano, R | 1 |
Noda, E | 1 |
Maeda, K | 1 |
Sawada, T | 3 |
Ohira, M | 4 |
Hirakawa, K | 5 |
Ohwada, Y | 1 |
Wang, X | 1 |
Wang, ML | 1 |
Zhou, LY | 1 |
Lu, XY | 1 |
Yang, JF | 1 |
Yu, HG | 1 |
Iizuka, R | 1 |
Kakihara, N | 1 |
Matsumura, H | 1 |
Takenaka, A | 1 |
Imazu, H | 1 |
Ochiai, M | 1 |
Sakurai, Y | 1 |
Matsubara, T | 1 |
Nozoe, Y | 1 |
Monden, M | 4 |
Ito, K | 1 |
Akiyama, S | 1 |
Nakao, A | 1 |
Tatematsu, M | 1 |
Baba, H | 1 |
Endo, K | 1 |
Ikeda, Y | 1 |
Toh, Y | 1 |
Kohnoe, S | 1 |
Okamura, T | 1 |
Nagashima, F | 1 |
Muto, M | 2 |
Sano, Y | 1 |
Mera, K | 1 |
Yano, T | 2 |
Doi, T | 2 |
Yoshida, S | 3 |
Konishi, K | 2 |
Kobayashi, O | 3 |
Sairenji, M | 2 |
Motohashi, H | 2 |
Usuki, H | 2 |
Ishimura, K | 1 |
Yachida, S | 2 |
Hagiike, M | 2 |
Okano, K | 1 |
Izuishi, K | 2 |
Karasawa, Y | 2 |
Maeta, H | 2 |
Tsujitani, S | 2 |
Kaibara, N | 1 |
Fujiwara, H | 2 |
Takagane, A | 1 |
Abe, K | 1 |
Irinoda, T | 1 |
Nakaya, T | 1 |
Yonezawa, H | 1 |
Kanzaki, N | 1 |
Ohtani, S | 2 |
Nemoto, T | 1 |
Hoshino, Y | 1 |
Kogure, M | 1 |
Naka, Y | 1 |
Fujikawa, M | 1 |
Fujii, M | 1 |
Emoto, T | 1 |
Komaki, T | 1 |
Adachi, I | 1 |
Kamei, A | 1 |
Hokita, S | 1 |
Takatori, H | 1 |
Ishigami, S | 1 |
Miyazono, F | 1 |
Arima, H | 1 |
Natsugoe, S | 1 |
Takao, S | 1 |
Aikou, T | 1 |
Hamada, N | 1 |
Nakagawa, A | 1 |
Ichiki, M | 1 |
Sai, K | 1 |
Sugawara, H | 1 |
Wada, H | 1 |
Kozuma, Y | 1 |
Kittaka, N | 2 |
Kim, T | 1 |
Takiuchi, D | 4 |
Aihara, T | 3 |
Fukunaga, M | 2 |
Ozato, H | 1 |
Tomita, N | 4 |
Kitamura, Y | 1 |
Hayashi, K | 3 |
Sasagawa, T | 1 |
Oguma, H | 1 |
Takasaki, K | 1 |
Shima, Y | 1 |
Horimi, T | 1 |
Nishioka, Y | 1 |
Okabayashi, T | 1 |
Hamada, M | 1 |
Ishikawa, T | 3 |
Shibuya, Y | 1 |
Sakurama, K | 1 |
Nishie, M | 1 |
Iwata, J | 1 |
Arai, W | 1 |
Hosoya, Y | 1 |
Saito, S | 1 |
Hirashima, Y | 2 |
Hyodo, M | 1 |
Yasuda, Y | 1 |
Nagai, H | 1 |
Shirasaka, T | 1 |
Takashima, T | 2 |
Yamagata, S | 2 |
Fukunaga, S | 1 |
Yashiro, M | 2 |
Nakata, B | 3 |
Taguchi, S | 1 |
Osugi, H | 1 |
Takemura, M | 1 |
Lee, S | 1 |
Nishizawa, S | 1 |
Iwasaki, H | 1 |
Mikata, S | 1 |
Higaki, J | 1 |
Yoshikawa, S | 1 |
Ide, H | 1 |
Kim, H | 1 |
Oimatsu, N | 1 |
Inayama, M | 1 |
Kamiike, W | 1 |
Souma, I | 1 |
Hayashi, N | 1 |
Izawa, H | 1 |
Sakita, I | 1 |
Hasuike, Y | 1 |
Fujimoto, T | 1 |
Yamada, K | 1 |
Sugiyama, Y | 1 |
Seino, K | 1 |
Kobori, H | 1 |
Maruyama, M | 1 |
Shibata, S | 1 |
Kawasaki, H | 1 |
Sasaki, M | 1 |
Kuriyama, H | 1 |
Nonaka, T | 1 |
Sawatari, T | 1 |
Tsuboi, H | 1 |
Akanuma, M | 1 |
Hata, Y | 1 |
Fujita, S | 1 |
Ooka, M | 1 |
Okajima, S | 1 |
Tsuboi, Y | 1 |
Akamoto, S | 1 |
Okada, S | 1 |
Hamai, Y | 1 |
Ukon, K | 1 |
Toge, T | 1 |
Komoto, M | 1 |
Nomura, S | 1 |
Kubota, T | 2 |
Akatsu, Y | 1 |
Yoshida, M | 2 |
Otani, Y | 2 |
Kumai, K | 2 |
Koufuji, K | 1 |
Aoyagi, K | 1 |
Yano, S | 1 |
Murakami, N | 1 |
Miyagi, M | 1 |
Imaizumi, T | 1 |
Shirouzu, K | 1 |
Seshimo, A | 1 |
Mitsuhashi, M | 1 |
Aratake, K | 1 |
Ogawa, S | 1 |
Itabashi, M | 1 |
Shirotani, N | 1 |
Kameoka, S | 1 |
Ishihara, C | 1 |
Noguchi, Y | 1 |
Ando, K | 1 |
Shotsu, M | 1 |
Ishiwa, N | 1 |
Takeda, A | 1 |
Ogoshi, T | 1 |
Endou, Y | 1 |
Tochiori, S | 1 |
Bando, E | 1 |
Kawamura, T | 1 |
Shimada, T | 1 |
Miyamoto, K | 1 |
Tanaka, M | 1 |
Kanda, T | 1 |
Banba, T | 1 |
Tanabe, T | 1 |
Kosugi, S | 1 |
Hatakeyama, K | 1 |
Takemoto, H | 1 |
Ooshiro, R | 1 |
Fujishima, M | 1 |
Tanaka, J | 1 |
Kondo, M | 3 |
Kishimoto, T | 1 |
Nakayama, T | 1 |
Masutani, S | 1 |
Tatsuta, M | 1 |
Kawasaki, T | 1 |
Koshikawa, K | 1 |
Kiriyama, K | 1 |
Wada, M | 1 |
Taniguchi, K | 1 |
Suenaga, H | 1 |
Kanazawa, S | 1 |
Seo, A | 1 |
Tokura, N | 1 |
Honda, R | 1 |
Kase, H | 1 |
Teramoto, T | 1 |
Tendo, M | 1 |
Nakazawa, K | 1 |
Yamada, N | 1 |
Aiko, S | 1 |
Yoshizumi, Y | 1 |
Sugiura, Y | 1 |
Ishizuka, T | 1 |
Sakano, T | 1 |
Kumano, I | 1 |
Maehara, T | 1 |
Kim, C | 2 |
Ohzato, H | 2 |
Koyama, F | 1 |
Kitajima, K | 1 |
Sugi, S | 1 |
Kagawa, K | 1 |
Kumamoto, T | 1 |
Murakami, K | 1 |
Fujioka, T | 1 |
Yamada, R | 1 |
Hatori, S | 1 |
Kunisaki, C | 1 |
Kanamaru, T | 1 |
Ishizone, S | 1 |
Maruta, F | 1 |
Koide, N | 1 |
Sugiyama, A | 2 |
Nakayama, J | 1 |
Miyagawa, S | 1 |
Munakata, M | 1 |
Sakata, Y | 1 |
Ishii, E | 1 |
Wada, R | 1 |
Nishiura, H | 1 |
Ishii, K | 1 |
Nonami, M | 1 |
Shigemori, M | 1 |
Katsurada, A | 1 |
Azechi, H | 1 |
Tojo, M | 1 |
Asagoe, K | 1 |
Inoue, F | 1 |
Suwa, H | 1 |
Saiga, T | 1 |
Hara, A | 1 |
Tsunemi, S | 1 |
Izumi, N | 1 |
Iwamoto, S | 1 |
Ichikawa, D | 1 |
Okamoto, K | 1 |
Sakakura, C | 1 |
Otsuji, E | 1 |
Sonoyama, T | 1 |
Hagiwara, A | 1 |
Yamagishi, H | 1 |
Sugiyama, S | 1 |
Miyade, Y | 1 |
Murakami, S | 1 |
Samejima, R | 1 |
Sumi, K | 1 |
Hidaka, K | 1 |
Uno, H | 1 |
Kayo, S | 1 |
Kawamura, C | 1 |
Mizuyama, Y | 1 |
Kaneda, K | 1 |
Nakagawa, H | 1 |
Arakawa, T | 1 |
Hosokawa, A | 1 |
Sugiyama, T | 1 |
Hattori, S | 1 |
Okuda, N | 1 |
Ichikawa, K | 1 |
Yamaoka, T | 1 |
Katou, T | 1 |
Wada, N | 1 |
Mizutani, S | 1 |
Oyama, T | 1 |
Uchikoshi, F | 1 |
Yoshidome, K | 1 |
Tori, M | 1 |
Hiraoka, K | 1 |
Yamagami, Y | 1 |
Nakahara, M | 1 |
Fukushima, N | 1 |
Nashimoto, A | 1 |
Ohta, T | 1 |
Narahara, H | 1 |
Yamaki, S | 1 |
Iwata, S | 1 |
Ohtsuka, K | 1 |
Kitaoka, A | 1 |
Masumoto, H | 1 |
Takayanagi, H | 1 |
Karaki, H | 1 |
Suzuki, H | 1 |
Yamamori, H | 1 |
Sugano, I | 1 |
Matsuyama, A | 1 |
Kameyama, T | 1 |
Okamoto, M | 1 |
Okazaki, J | 1 |
Utsunomiya, T | 1 |
Tsutsui, S | 1 |
Iwahashi, M | 1 |
Tani, M | 1 |
Sakaguchi, S | 1 |
Ueda, K | 1 |
Ichiro, M | 1 |
Nishino, E | 1 |
Tanimura, H | 1 |
Inaba, Y | 1 |
Watabe, S | 1 |
Ohe, S | 1 |
Kamio, Y | 1 |
Koyama, M | 1 |
Chiba, M | 1 |
Kanari, M | 1 |
Morikawa, A | 1 |
Okabe, R | 1 |
Miyazawa, K | 1 |
Iijima, S | 1 |
Ozaki, K | 1 |
Koyama, Y | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase I/II, Single-center, Single-arm, Open-label Study of Nanoparticle Albumin-bound-paclitaxel (Nab-PTX) Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer[NCT04781413] | Phase 1/Phase 2 | 38 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
Docetaxel, Oxaliplatin, Fluorouracil (FLOT Regimen) Combined With Teriprizumab (PD-1) in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis: an Open, One-arm, Exploratory Study[NCT04886193] | 20 participants (Anticipated) | Interventional | 2021-04-16 | Recruiting | |||
The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer[NCT03007446] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910] | Phase 1 | 36 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | ||
Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin. Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin and in Combination With Nivolumab in Patients With Peritoneal Carcinomat[NCT03172416] | Phase 1 | 21 participants (Anticipated) | Interventional | 2017-04-12 | Recruiting | ||
Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
13 reviews available for oxonic acid and Peritoneal Carcinomatosis
Article | Year |
---|---|
[A Case of Remnant Gastric Cancer That Completely Responded to Neoadjuvant S-1 and Cisplatin Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hum | 2017 |
[A Case of QOL Improvement after Intestinal Stenosis Due to Peritoneal Dissemination of Gastric Cancer in Elderly Patients].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Fe | 2017 |
[Curative resection of a case of advanced gastric cancer with peritoneal dissemination responding well to combination chemotherapy of docetaxel,cisplatin and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe | 2013 |
[A case of jejnal cancer who was controlled peritoneal metastasis, successfully by combination therapy with docetaxel and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Jejunal Neopla | 2013 |
[A case of effective treatment with S-1/gemcitabine chemotherapy and resection for advanced pancreatic cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug | 2014 |
[A case of highly advanced gastric cancer with peritoneal dissemination -- a histological CR to S-1 and CDDP combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Middle A | 2015 |
Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian | 2015 |
[Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doceta | 2015 |
A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytoreduction Surgical Procedures; Doceta | 2016 |
The Importance of Extensive Intraoperative Peritoneal Lavage as a Promising Method in Patients with Gastric Cancer Showing Positive Peritoneal Cytology Without Overt Peritoneal Metastasis and Other Therapeutic Approaches.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Infusions, Parenteral; Intraoperative Ca | 2017 |
Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Drug Combinations; | 2010 |
[A case of scirrhous gastric carcinoma with peritoneal dissemination which was treated by curative gastrectomy after S-1/CDDP chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinati | 2010 |
[A case of peritoneal dissemination that exhibited a complete response to systemic chemotherapy following the resection of primary colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colostomy; Combined Modality Ther | 2012 |
37 trials available for oxonic acid and Peritoneal Carcinomatosis
Article | Year |
---|---|
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplas | 2022 |
Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2020 |
Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Dr | 2021 |
The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy.
Topics: Aged; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; M | 2017 |
Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combina | 2017 |
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; H | 2018 |
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug | 2019 |
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2019 |
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, | 2013 |
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2013 |
Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2014 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin | 2016 |
Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; F | 2016 |
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancr | 2017 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
[Clinical trials of neo-adjuvant chemotherapy for advanced gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Co | 2008 |
[Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastric Lavage | 2008 |
Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 2009 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Follow-Up St | 2010 |
Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; D | 2010 |
Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Surviva | 2010 |
Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; D | 2010 |
Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Femal | 2010 |
Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Drug Combinations; Female; H | 2011 |
[The updated treatment strategy for gastric cancer with peritoneal metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2012 |
A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Comb | 2012 |
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydroge | 2013 |
Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combin | 2013 |
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2003 |
Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2003 |
Pilot study of S-1 in patients with disseminated gastric cancer.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Drug Combinations; Female; Humans; | 2003 |
[Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; F | 2007 |
[A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Infusions, Par | 2007 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
[The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Femal | 2002 |
165 other studies available for oxonic acid and Peritoneal Carcinomatosis
Article | Year |
---|---|
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Ge | 2022 |
Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Oxaliplatin; | 2022 |
Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2020 |
[A Long Term Survival Case of Gastric Cancer with Peritoneal Dissemination Responding to Intraperitoneal Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Human | 2020 |
[A Case of Advanced Gastric Cancer with Peritoneal Metastasis Achieved Pathological Complete Response by Chemotherapy(SOX Regimen)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans | 2020 |
Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Combined Moda | 2017 |
[A Case of Unresectable Gastric Cancer with Multiple Metastases Responding to Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Liver Ne | 2017 |
[Advanced Gastric Cancer with Peritoneal Dissemination Treated with Conversion Surgery after S-1 and CDDP Chemotherapy - A Case Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; | 2018 |
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Stud | 2018 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2018 |
[Three Cases of Advanced Gastric Cancer with Peritoneal Dissemination Successfully Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Gastrect | 2018 |
[A Case of Peritoneal Dissemination of Metastatic Gastric Cancer with Successful Docetaxel and S-1 Combination Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; M | 2018 |
[A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans | 2019 |
[Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Laparoscopy; | 2019 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations | 2014 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocol | 2013 |
[A case of AFP-producing gastric cancer with peritoneal metastasis treated effectively with chemotherapy, mainly using S-1 and trastuzumab].
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antine | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; | 2013 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2013 |
Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2014 |
[A case of gastric cancer with intensive peritoneal dissemination treated with long-term chemotherapy and surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinati | 2013 |
[A case of advanced gastric cancer with peritoneal dissemination recurrence after gastrectomy effectively treated with combination chemotherapy of S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Hum | 2013 |
[A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiothe | 2013 |
[Repeated occlusion of the intraperitoneal access port for intraperitoneal chemotherapy in a patient with gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Middle Aged; Oxonic | 2013 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
[A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; M | 2014 |
Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2014 |
[A case of a patient with gastric cancer and peritoneal dissemination who survived for more than 10 years after successful treatment with S-1].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; | 2014 |
[A case of gastric adenosquamous carcinoma with peritoneal dissemination in which treatment with S-1 plus paclitaxel therapy resulted in improved long-term survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Adenosquamous; Chemotherapy, Adju | 2014 |
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2015 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations | 2014 |
[Long-term disease-free survival by S-1 therapy in a case of gastric cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2014 |
[A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, | 2014 |
[A case of radical resection for pancreatic head cancer with peritoneal dissemination treated with combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; | 2014 |
[A case of advanced gastric cancer successfully treated with second-line chemotherapy followed by curative conversion gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug | 2014 |
[A case of successful treatment of peritoneal dissemination from gastric cancer with S-1/DOC chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Hum | 2014 |
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectom | 2015 |
Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Topics: Adult; Aged; Cisplatin; Docetaxel; Drug Combinations; Drug-Related Side Effects and Adverse Reaction | 2015 |
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Blood Proteins; | 2015 |
Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2015 |
[S-1 plus Cisplatin Combination Therapy for Gastric Cancer with Peritoneal Dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Com | 2015 |
[A Case of Long-Term Survival of a Patient with Gastric Cancer with Peritoneal Dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy | 2015 |
[A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug C | 2015 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination Effectively Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doceta | 2015 |
[Introduction of Chemotherapy for Advanced Gastric Cancer Showing Oncologic Emergency Caused by Peritoneal Dissemination--Report of Tow Cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Ileus; Jaundice, | 2015 |
[A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fat | 2016 |
[Pathological Complete Response to SOX plus Bevacizumab for Treating Stage IV Sigmoid Colon Cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Constipation; Drug Comb | 2016 |
[Outcomes of Staging Laparoscopy in Eight Patients with Positive Peritoneal Washing Cytology after S-1 Administration].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combin | 2016 |
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2017 |
[A Case of Advanced Gastric Cancer Successfully Treated with Curative Conversion Surgery after Chemotherapy with S-1 plus Oxaliplatin].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; | 2016 |
[A case of gastric cancer with peritoneal dissemination responding to combination chemotherapy with oral fluoropyrimidine and weekly paclitaxel].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 2008 |
[A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinat | 2008 |
[A case of peritoneal disseminated sigmoid colon cancer with liver metastasis responding to S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Humans; | 2008 |
Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
[A case of scirrhous gastric cancer with peritoneal dissemination acquiring stable disease over three years by treatment with oral anticancer drug S-1].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 2008 |
[A case of perforated gastric cancer in which resection for elimination was possible S-1/CDDP combined chemotherapy for peritonitis carcinomatosa].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastroscopy; Hum | 2009 |
[Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2009 |
[A case of gastric cancer with peritoneal dissemination-efficacy of combination therapy with S-1 and docetaxel].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2009 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug | 2009 |
[Outcome of therapy for type 4 gastric cancer with peritoneal metastasis--diagnosis by laparoscopy and effect of chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2009 |
[A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2009 |
[A case of far-advanced gastric cancer with peritoneal dissemination and obstructive jaundice effectively treated with combination chemotherapy and interventional radiology].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine | 2009 |
[Two cases of advanced gastric cancer with peritoneal dissemination, and Virchow's metastases successfully treated by combination therapy of S-1 and docetaxel].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
[A case of type 4 gastric cancer with peritoneal dissemination complicating venous thromboembolism treated effectively by combination of S-1 and warfarin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Drug Combinations | 2010 |
Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Adm | 2010 |
[Strategy of treatment for gastric cancer with peritoneal metastasis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combin | 2010 |
Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Hum | 2010 |
[S-1-based chemotherapy for recurrent gastric cancer with peritoneal dissemination resulting in long-term survival--report of a case].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic | 2010 |
[A very elderly case of recurrent gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of docetaxel (DOC) and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Com | 2010 |
[Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
Topics: Administration, Oral; Animals; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Drug Com | 2010 |
[The effects of gastrojejunostomy for patients with advanced gastric cancer accompanied by peritoneal dissemination].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastric Bypass; | 2010 |
[An effective treatment by chemotherapy with S-1 and CDDP intraperitoneal administration for the peritoneal dissemination of gastric cancer--a case report].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2010 |
[A case of gastric cancer with peritoneal dissemination successfully treated by S-1/paclitaxel combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastroscopy; Humans; Midd | 2011 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2011 |
Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Cisplatin; Dr | 2011 |
[A case of gastric carcinoma with peritoneal metastasis successfully treated by combination chemotherapy of S-1 and cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Therapy; | 2011 |
[Primary adenocarcinoma of small intestine with peritoneal dissemination treated with S-1 and CPT-11 combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2011 |
[A case of unresectable advanced gastric cancer treated with S-1/low-dose CDDP combination chemotherapy through jejunostomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Com | 2011 |
Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Ther | 2012 |
Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Co | 2012 |
[A case report of the combination therapy with S-1 plus CDDP intraperitoneal chemotherapy for CY positive cancer patient].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; | 2011 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinat | 2011 |
[Peritoneal lavage cytology under local anesthesia for detection of peritoneal recurrence after surgery].
Topics: Aged; Anesthesia, Local; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combination | 2011 |
[A case of advanced gastric cancer with peritoneal dissemination successfully treated with S-1 and intraperitoneal docetaxel administration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; | 2012 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
[Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dihydrouracil Dehydrogenase (NADP); D | 2012 |
[A case report of advanced gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Male; Ne | 2012 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Docetaxel; D | 2012 |
[A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fatal Outcome; Humans; Male; Midd | 2012 |
Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Drainage; | 2012 |
[A case of gastric cancer with peritoneal dissemination and massive ascites successfully treated with S-1/docetaxel therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Docetaxel; Drug Combinations; Femal | 2012 |
[S-1 monotherapy achieved twenty-month survival for peritoneal lavage cytology-positive gastric cancer patient undergoing noncurative resection].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Ga | 2012 |
[A case of far-advanced gastric cancer successfully treated with S-1/paclitaxel/krestin immunochemotherapy, followed by curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Immunotherapy; Li | 2012 |
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinati | 2002 |
[A surgically resected case of advanced gastric carcinoma with peritoneal dissemination after treatment with combined chemotherapy of TS-1 and CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2003 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2003 |
Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Carcinoma; Cell Count; Dose | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Drug Evaluation; Fe | 2003 |
Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; D | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
[A case of peritoneal metastasis of gastric cancer responding to TS-1, administered for four consecutive weeks with two-week rests].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Ma | 2003 |
[A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colonic Di | 2003 |
[Efficacy of TS-1 in patients with peritonitis carcinomatosa from gastric cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedul | 2003 |
[A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2003 |
[Two resected cases of advanced gastric cancer with peritoneal dissemination after successful treatment with TS-1 plus low-dose CDDP].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2003 |
[A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Drug Administration Sc | 2004 |
[A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplat | 2004 |
[A case of advanced colon cancer with peritoneal dissemination completely responding to TS-1].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; | 2004 |
[TS-1 was prescribed for a patient with stomach cancer with peritoneal dissemination who survived for 3 years and 2 months].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration | 2004 |
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase | 2004 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined M | 2004 |
[A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration | 2005 |
[A case of advanced gastric cancer with peritoneal dissemination effectively treated by combined chemotherapy of paclitaxel (TXL) and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administration Sch | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
[TS-1 therapy via intestinal catheter used for tube feeding in a patient with gastric cancer after total gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Catheterization; Combined Modality Therapy; Drug Administrati | 2005 |
[A case of remnant gastric cancer with multiple bone metastasis and peritoneal dissemination; efficacy of combination therapy of docetaxel and TS-1].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modal | 2005 |
[A case of gastric cancer with peritoneal recurrence which developed during adjuvant administration of TS-1 showing complete response by weekly docetaxel regimen].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; | 2005 |
[Preoperative combination chemotherapy with TS-1 is effective in a case gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Drug Administrat | 2005 |
[Peritoneal dissemination of scirrhous type 4 gastric cancers].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 2005 |
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Flu | 2005 |
[Prediction and treatment of peritoneal dissemination in gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combination | 2005 |
[Two cases of advanced gastric cancer, successfully treated with TS-1/CDDP combination chemotherapy--case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2005 |
[Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; | 2005 |
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2005 |
[A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
[Two cases of advanced gastric cancer with peritoneal dissemination acquired long-term response three years or more by postoperative treatment with oral anticancer drug TS-1].
Topics: Adenocarcinoma, Mucinous; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Combined Moda | 2006 |
[Liver metastasis from sigmoid colon cancer with peritoneal dissemination showed a complete response to TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryoni | 2006 |
A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
Topics: Adenocarcinoma, Scirrhous; Animals; Antimetabolites, Antineoplastic; Benzenesulfonates; Cyclooxygena | 2006 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2006 |
[Two cases of gastric cancer with peritoneal dissemination that responded to TS-1 without progression or recurrence for over 3 years].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug | 2006 |
[A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Docetax | 2006 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2006 |
[Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Adminis | 2006 |
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Drug Combinations; Female; Fl | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administra | 2006 |
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Dihydrouracil Dehydrogenase (NADP); | 2006 |
[A case of duodenal carcinoma with massive peritoneal carcinomatosis complicating a pulmonary embolism].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug T | 2006 |
[A case of advanced gastric cancer with peritoneal dissemination responding remarkably to TS-1/CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2006 |
[A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Comb | 2006 |
[Two cases of primary peritoneal cystadenocarcinoma--diagnosis, treatment, and clinical feature].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcino | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; | 2007 |
[A case of advanced gastric cancer with peritoneal dissemination effectively treated with fourth-line chemotherapy of S-1 alone].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinati | 2007 |
[Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Drug Administration Schedule; Dr | 2007 |
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Combi | 2007 |
[Prolonged complete response obtained by single agent S-1 in a case of peritoneal metastasis from gastric remnant cancer].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gastric Stump; Humans; Male; Middle Aged; Neopla | 2007 |
[Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2007 |
[A case of advanced gastric cancer with peritoneal dissemination responding to S-1/CDDP neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2007 |
Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2007 |
[A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
[A case of advanced gastric cancer with Schnitzler's metastases effectively treated by the combination of paclitaxel and S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 2001 |
Unusual survival for more than 2 years with peritoneal metastases of gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
[Evaluation of the efficacy of TS-1 for peritoneal dissemination of gastric cancer using a newly-developed animal model].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2002 |